Role of Serotonin in Modulation of Decision-making in Parkinson's Disease

Overview

Journal J Psychopharmacol

Publisher Sage Publications

Specialty Pharmacology

Date 2023 Jan 11

PMID 36628992

Authors

Lisa Nobis

Maria Raquel Maio

Youssuf Saleh

Sanjay Manohar

Annika Kienast

Emily McGann

Masud Husain

Affiliations

Soon will be listed here.

Abstract

Background: Dysfunction of dopaminergic pathways has been considered to play a pivotal role in Parkinson's disease (PD), affecting the processing of emotional and rewarding information, and potentially leading to symptoms of depression or apathy. However, some aspects of motivation in PD might be affected by non-dopaminergic mechanisms.

Aim And Method: The objective of this experimental medicine study was to investigate the contribution of serotonergic modulation via administration of citalopram (20 mg) for 7 days on motivated decision-making in twenty PD patients, measured using several different computerised tasks and clinical questionnaires that probe different aspects of decision-making. Twenty healthy controls were additionally tested without medication to assess any baseline differences between the two groups.

Results: Results indicated that PD patients were overall less motivated than controls on an effort- and reward-based decision-making task. Citalopram increased or decreased willingness to exert effort for reward, depending on whether baseline motivation was high or low, respectively. A task assessing decision-making under risk revealed higher levels of risk aversion for potential losses in PD patients, which neither serotonin nor the patient's regular dopaminergic medication seemed to restore. However, citalopram in PD was associated with more risk-seeking choices for gains, although patients and controls did not differ on this at baseline.

Conclusion: The results provide evidence for a role of the serotonergic system in influencing some aspects of motivated decision-making in PD processes.

References

Morel P, Ulbrich P, Gail A . What makes a reach movement effortful? Physical effort discounting supports common minimization principles in decision making and motor control. PLoS Biol. 2017; 15(6):e2001323. PMC: 5460791. DOI: 10.1371/journal.pbio.2001323. View

Chong T, Husain M . The role of dopamine in the pathophysiology and treatment of apathy. Prog Brain Res. 2016; 229:389-426. DOI: 10.1016/bs.pbr.2016.05.007. View

Kranz G, Kasper S, Lanzenberger R . Reward and the serotonergic system. Neuroscience. 2010; 166(4):1023-35. DOI: 10.1016/j.neuroscience.2010.01.036. View

Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K . Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004; 318(1):121-34. DOI: 10.1007/s00441-004-0956-9. View

Tanaka S, Shishida K, Schweighofer N, Okamoto Y, Yamawaki S, Doya K . Serotonin affects association of aversive outcomes to past actions. J Neurosci. 2009; 29(50):15669-74. PMC: 6666190. DOI: 10.1523/JNEUROSCI.2799-09.2009. View

Pagonabarraga J, Kulisevsky J, Strafella A, Krack P . Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 2015; 14(5):518-31. DOI: 10.1016/S1474-4422(15)00019-8. View

Argaud S, Verin M, Sauleau P, Grandjean D . Facial emotion recognition in Parkinson's disease: A review and new hypotheses. Mov Disord. 2018; 33(4):554-567. PMC: 5900878. DOI: 10.1002/mds.27305. View

Li Y, Zhong W, Wang D, Feng Q, Liu Z, Zhou J . Serotonin neurons in the dorsal raphe nucleus encode reward signals. Nat Commun. 2016; 7:10503. PMC: 4738365. DOI: 10.1038/ncomms10503. View

Graef S, Biele G, Krugel L, Marzinzik F, Wahl M, Wotka J . Differential influence of levodopa on reward-based learning in Parkinson's disease. Front Hum Neurosci. 2010; 4:169. PMC: 2967381. DOI: 10.3389/fnhum.2010.00169. View

10.

Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson I . The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord. 2009; 118(1-3):87-93. DOI: 10.1016/j.jad.2009.01.028. View

11.

Crockett M, Clark L, Hauser M, Robbins T . Serotonin selectively influences moral judgment and behavior through effects on harm aversion. Proc Natl Acad Sci U S A. 2010; 107(40):17433-8. PMC: 2951447. DOI: 10.1073/pnas.1009396107. View

12.

McGuigan S, Zhou S, Brosnan M, Thyagarajan D, Bellgrove M, Chong T . Dopamine restores cognitive motivation in Parkinson's disease. Brain. 2019; 142(3):719-732. DOI: 10.1093/brain/awy341. View

13.

Seppi K, Chaudhuri K, Coelho M, Fox S, Katzenschlager R, Perez Lloret S . Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019; 34(2):180-198. PMC: 6916382. DOI: 10.1002/mds.27602. View

14.

Moonen A, Wijers A, Dujardin K, Leentjens A . Neurobiological correlates of emotional processing in Parkinson's disease: A systematic review of experimental studies. J Psychosom Res. 2017; 100:65-76. DOI: 10.1016/j.jpsychores.2017.07.009. View

15.

Le Heron C, Apps M, Husain M . The anatomy of apathy: A neurocognitive framework for amotivated behaviour. Neuropsychologia. 2017; 118(Pt B):54-67. PMC: 6200857. DOI: 10.1016/j.neuropsychologia.2017.07.003. View

16.

Harmer C, Shelley N, Cowen P, Goodwin G . Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004; 161(7):1256-63. DOI: 10.1176/appi.ajp.161.7.1256. View

17.

Izumi T, Inoue T, Kitaichi Y, Nakagawa S, Koyama T . Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor. Eur J Pharmacol. 2006; 534(1-3):129-32. DOI: 10.1016/j.ejphar.2005.12.073. View

18.

Liu Z, Zhou J, Li Y, Hu F, Lu Y, Ma M . Dorsal raphe neurons signal reward through 5-HT and glutamate. Neuron. 2014; 81(6):1360-1374. PMC: 4411946. DOI: 10.1016/j.neuron.2014.02.010. View

19.

Le Heron C, Plant O, Manohar S, Ang Y, Jackson M, Lennox G . Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson's disease. Brain. 2018; 141(5):1455-1469. PMC: 5917786. DOI: 10.1093/brain/awy110. View

20.

Ye Z, Altena E, Nombela C, Housden C, Maxwell H, Rittman T . Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain. 2014; 137(Pt 4):1145-55. PMC: 3959561. DOI: 10.1093/brain/awu032. View